{"nctId":"NCT01517802","briefTitle":"A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate","startDateStruct":{"date":"2012-03-28","type":"ACTUAL"},"conditions":["Metastatic Castration-resistant Prostate Cancer","Metastatic Breast Cancer"],"count":32,"armGroups":[{"label":"Abiraterone acetate","type":"EXPERIMENTAL","interventionNames":["Drug: Abiraterone acetate","Drug: Prednisone"]}],"interventions":[{"name":"Abiraterone acetate","otherNames":[]},{"name":"Prednisone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Currently participating in an abiraterone acetate clinical study considered complete and had received at least 3 months of treatment with abiraterone acetate tablets.\n\nExclusion Criteria:\n\n* Medical conditions that require hospitalization.\n* Any condition or situation which, in the opinion of the investigator, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":31},"commonTop":["Lower Respiratory Tract Infection","Urinary Tract Infection","Dehydration","Cerebrovascular Accident","Encephalopathy"]}}}